GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Durata Therapeutics Inc (FRA:DTA) » Definitions » Gross Margin %

Durata Therapeutics (FRA:DTA) Gross Margin % : 0.00% (As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is Durata Therapeutics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Durata Therapeutics's Gross Profit for the three months ended in Sep. 2014 was €7.82 Mil. Durata Therapeutics's Revenue for the three months ended in Sep. 2014 was €7.82 Mil. Therefore, Durata Therapeutics's Gross Margin % for the quarter that ended in Sep. 2014 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Durata Therapeutics's Gross Margin % or its related term are showing as below:

FRA:DTA' s Gross Margin % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 100
Current: 100


During the past 3 years, the highest Gross Margin % of Durata Therapeutics was 100.00%. The lowest was 0.00%. And the median was 0.00%.

FRA:DTA's Gross Margin % is not ranked
in the Biotechnology industry.
Industry Median: 59.43 vs FRA:DTA: 100.00

Durata Therapeutics had a gross margin of N/A% for the quarter that ended in Sep. 2014 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Durata Therapeutics was 0.00% per year.


Durata Therapeutics Gross Margin % Historical Data

The historical data trend for Durata Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Durata Therapeutics Gross Margin % Chart

Durata Therapeutics Annual Data
Trend Dec11 Dec12 Dec13
Gross Margin %
- - -

Durata Therapeutics Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Durata Therapeutics's Gross Margin %

For the Biotechnology subindustry, Durata Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Durata Therapeutics's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Durata Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Durata Therapeutics's Gross Margin % falls into.



Durata Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Durata Therapeutics's Gross Margin for the fiscal year that ended in Dec. 2013 is calculated as

Gross Margin % (A: Dec. 2013 )=Gross Profit (A: Dec. 2013 ) / Revenue (A: Dec. 2013 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

Durata Therapeutics's Gross Margin for the quarter that ended in Sep. 2014 is calculated as


Gross Margin % (Q: Sep. 2014 )=Gross Profit (Q: Sep. 2014 ) / Revenue (Q: Sep. 2014 )
=7.8 / 7.823
=(Revenue - Cost of Goods Sold) / Revenue
=(7.823 - 0) / 7.823
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Durata Therapeutics  (FRA:DTA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Durata Therapeutics had a gross margin of N/A% for the quarter that ended in Sep. 2014 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Durata Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Durata Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Durata Therapeutics (FRA:DTA) Business Description

Traded in Other Exchanges
N/A
Address
Durata Therapeutics Inc was incorporated under the laws of the State of Delaware on November 4, 2009. The Company, along with its subsidiaries, is a development stage pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The Company recently completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing.

Durata Therapeutics (FRA:DTA) Headlines

No Headlines